液体活检在胰腺癌中的研究进展

国际肿瘤学杂志››2018,Vol. 45››Issue (3): 180-182.doi:10.3760/cma.j.issn.1673-422X.2018.03.012

液体活检在胰腺癌中的研究进展

李志坚，贺德

524023 湛江，广东医科大学研究生院（李志坚）；南方医科大学附属深圳宝安医院普通外科（李志坚、贺德）

收稿日期:2017-12-21出版日期:2018-03-08发布日期:2018-05-16
通讯作者:贺德 E-mail:贺德，Email: hede1965@126.com
基金资助:
深圳市科技计划（JCYJ20160427192617570）

Research progress on liquid biopsy in pancreatic cancer

Li Zhijian, He De

Postgraduate College of Guangdong Medical University, Zhanjiang 524023, China; Department of General Surgery, Affiliated Bao′an Hospital of Southern Medical University, Shenzhen 518101, China

Received:2017-12-21Online:2018-03-08Published:2018-05-16
Contact:He De E-mail:贺德，Email: hede1965@126.com
Supported by:
Science and Technology Program of Shenzhen of China (JCYJ20160427192617570）

摘要/Abstract

摘要：液体活检是一类热门且新兴的病理检测技术，主要包括肿瘤循环细胞检测、肿瘤循环DNA检测以及外泌体检测，近年来研究显示该技术不仅在胰腺癌早期诊断中发挥着潜在的优势，而且对肿瘤的预后判断以及复发监测有一定的指导意义。

李志坚，贺德. 液体活检在胰腺癌中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(3): 180-182.

Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer[J]. Journal of International Oncology, 2018, 45(3): 180-182.

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387. ［2］ Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Res, 2014, 74(11): 29132921. DOI: 10.1158/00085472.CAN140155. ［3］ Seufferlein T, Mayerle J. Pancreatic cancer in 2015: precision medicine in pancreatic cancer—fact or fiction?［J］. Nat Rev Gastroenterol Hepatol, 2016, 13(2): 74-75. DOI: 10.1038/nrgastro.2015.215. ［4］ Millner LM, Strotman LN. The future of precision medicine in oncology［J］. Clin Lab Med, 2016, 36(3): 557-573. DOI: 10.1016/j.cll.2016.05.003. ［5］ Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies［J］. Somatic Cell Genet, 1979, 5(6): 957-971. ［6］ Zhang Q, Chen S, Zeng L, et al. New developments in the early diagnosis of pancreatic cancer［J］. Expert Rev Gastroenterol Hepatol, 2017, 11(2): 149-156. DOI: 10.1080/17474124.2017.1271323. ［7］ Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 199 in pancreatic adenocarcinoma: diagnostic and prognostic updates［J］. Curr Mol Med, 2013, 13(3): 340-351. ［8］ Chang JC, Kundranda M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma［J］. Int J Mol Sci, 2017, 18(3): E667. DOI: 10.3390/ijms18030667. ［9］ Kim YJ, Koh HK, Chie EK, et al. Change in carbohydrate antigen 199 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy［J］. Int J Clin Oncol, 2017, 22(6): 1069-1075. DOI: 10.1007/s10147-017-1129. ［11］ Kulemann B, Pitman MB, Liss AS, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer［J］. Pancreas, 2015, 44(4): 547-550. DOI: 10.1097/MPA.0000000000000324. ［12］ Liu H, Sun B, Wang S, et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma［J］. Cell Physiol Biochem, 2017, 42(1): 373-382. DOI: 10.1159/000477481. ［13］ Ankeny JS, Court CM, Hou S, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer［J］. Br J Cancer, 2016, 114(12): 1367-1375. DOI: 10.1038/bjc.2016.121. ［14］ Tien YW, Kuo HC, Ho BI, et al. A high circulating tumor cell count in portal vein predicts liver metastasis from periampullary or pancreatic cancer: a high portal enous CTC count predicts liver metastases［J］. Medicine (Baltimore), 2016, 95(16): e3407. DOI: 10.1097/MD.0000000000003407. ［15］ Arnoletti JP, Zhu X, Almodovar AJ, et al. Portal venous blood circulation supports immunosuppressive environment and pancreatic cancer circulating tumor cell activation［J］. Pancreas, 2017, 46(1): 116-123. DOI: 10.1097/MPA.0000000000000667. ［16］ Poruk KE, Valero 3rd, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma［J］. Ann Surg, 2016, 264(6): 1073-1081. DOI: 10.1097/SLA.0000000000001600. ［17］ Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez I′homme［J］. Cr Acad Sci Paris, 1948, 142(3-4): 241-243. ［18］高芃, 李金明. 循环肿瘤DNA与肿瘤精准治疗［J］. 实用医院临床杂志, 2016, 13(3): 16. DOI: 10.3969/j.issn.16726170.2016.03.001. ［19］ Henriksen SD, Madsen PH, Larsen AC, et al. Cellfree DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma［J］. Clin Epigenetics, 2016, 8: 117. DOI: 10.1186/s1347801602862. ［20］ Henriksen SD, Madsen PH, Larsen AC, et al. Promoter hypermethylation in plasmaderived cellfree DNA as a prognostic marker for pancreatic adenocarcinoma staging［J］. Int J Cancer, 2017, 141(12): 24892497. DOI: 10.1002/ijc.31024. ［21］ Creemers A, Krausz S, Strijker M, et al. Clinical value of ctDNA in upperGI cancers: a systematic review and metaanalysis［J］. Biochim Biophys Acta, 2017, 1868(2): 394-403. DOI: 10.1016/j.bbcan.2017.08.002. ［22］ Singh N, Gupta S, Pandey RM, et al. High levels of cellfree circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival［J］. Cancer Invest, 2015, 33(3): 78-85. DOI: 10.3109/07357907.2014.1001894. ［23］ Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker［J］. Clin Cancer Res, 2017, 23(1): 116-123. DOI: 10.1158/1078-0432.CCR-16-0806. ［24］ Pan BT, Teng K, Wu C, et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes［J］. J Cell Biol, 1985, 101(3): 942948. ［25］ Steinbichler TB, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis［J］. Semin Cancer Biol, 2017, 44: 170-181. DOI: 10.1016/j.semcancer.2017.02.006. ［26］ Whiteside TL. Tumorderived exosomes and their role in cancer progression［J］. Adv Clin Chem, 2016, 74: 103-141. DOI: 10.1016/bs.acc.2015.12.005. ［27］ Melo SA, Luecke LB, Kahlert C, et al. Glypican1 identifies cancer exosomes and detects early pancreatic cancer［J］. Nature, 2015, 523(7559): 177-182. DOI: 10.1038/nature14581. ［28］ Lai X, Wang M, Mcelyea SD, et al. A microRNA signature in circulating exosomes is superior to exosomal glypican1 levels for diagnosing pancreatic cancer［J］. Cancer Lett, 2017, 393: 86-93. DOI: 10.1016/j.canlet.2017.02.019.

[1]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[2]	刘博翰, 黄俊星.液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[3]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[4]	张渊, 白芷玉, 李琪, 冯勤梅.外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488.
[5]	魁国菊, 黄江宾, 张文华, 杨立民.区域淋巴结大小对胰头腺癌术后复发的影响[J]. 国际肿瘤学杂志, 2023, 50(10): 608-613.
[6]	李洪宇, 乌新林.外泌体与结直肠癌肝转移[J]. 国际肿瘤学杂志, 2022, 49(12): 749-753.
[7]	王文浩, 孙希瑞, 刘锦, 孙秀梅.肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用[J]. 国际肿瘤学杂志, 2022, 49(10): 615-618.
[8]	张琬琛, 徐加杰, 张李卓, 葛明华.外泌体-环状RNA在肿瘤诊治中的临床意义[J]. 国际肿瘤学杂志, 2021, 48(9): 549-552.
[9]	庄伟涛, 乔贵宾.基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用[J]. 国际肿瘤学杂志, 2021, 48(6): 358-361.
[10]	严志颖, 毛逸锋, 朱颖蔚, 徐克群.癌相关成纤维细胞的异质性在靶向胰腺癌治疗中的角色[J]. 国际肿瘤学杂志, 2021, 48(5): 308-312.
[11]	中国医师协会放射肿瘤治疗医师分会.胰腺癌立体定向放疗(放射外科)指南[J]. 国际肿瘤学杂志, 2021, 48(11): 643-648.
[12]	钟扬, 何苗, 刘志, 陈建宇, 张光年, 秦龙, 李婷, 李建水.麦冬皂苷D联合沉默环氧合酶-2基因对人胰腺癌BxPC-3细胞增殖、迁移和侵袭的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 583-590.
[13]	李珂珂, 孔盼盼, 易超, 王喜艳, 晏冬.淋巴样增强因子-1在胰腺导管腺癌中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 608-613.
[14]	陈晓旭, 于洋, 张天雪.基于免疫相关lncRNA建立胰腺癌预后风险评估模型[J]. 国际肿瘤学杂志, 2020, 47(8): 472-479.
[15]	杜明丽, 李桂香, 吴文娟, 赵磊.循环肿瘤DNA在转移性黑色素瘤靶向治疗及免疫治疗中的应用[J]. 国际肿瘤学杂志, 2020, 47(6): 381-384.